InvestorsObserver is giving CymaBay Therapeutics Inc (CBAY) an Analyst Rating Rank of 74, meaning CBAY is ranked higher by analysts than 74% of stocks. The average price target for CBAY is $11.25 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating CBAY a Strong Buy today. Find out what this means to you and get the rest of the rankings on CBAY!
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With CymaBay Therapeutics Inc Stock Today?
CymaBay Therapeutics Inc (CBAY) stock is trading at $4.08 as of 2:24 PM on Wednesday, Nov 17, a drop of -$0.16, or -3.81% from the previous closing price of $4.24. The stock has traded between $4.05 and $4.27 so far today. Volume today is below average. So far 214,188 shares have traded compared to average volume of 423,870 shares.
Click Here to get the full Stock Report for CymaBay Therapeutics Inc stock.